Try our Advanced Search for more refined results
Life Sciences - July, 2015
301 articles
- USPTO Patent Guidance Has Attys Fearing Wave Of Rejections
- Covidien Urges Supreme Court To Hear 'Secret' Prior Art Row
- Taxation With Representation: Sullivan, Wachtell, MoFo
- Credit Union's Suit Could Open Up Banking For Pot Business
- Forest Labs Says Sex-Bias Plaintiffs Lack Evidence
- Gunderson Nabs Ex-DLA Partners To Boost Calif. Offices
- 10 IPOs Targeting $1.4B Ready To Rock 1st Week Of August
- Fed. Circ. Says Judge Got X-Ray Patent Wrong, Revives Suit
- 7th Circ. Refuses To Adopt Tighter Class Cert. Standard
- Medicare Does Not Cover Lab's Cancer Test, Judge Rules
- London Calling: On The Cusp Of A UK Biotech Revolution
- $400M Pfizer Class Action Deal Gets OK From Judge
- 7 Keys To Improving Your Direct Examination
- Nexium Judge Gives Rare Look Into Landmark Antitrust Trial
- Cephalon Can't Dodge Provigil Claims In FCA Off-Label Suit
- No New Trial For Drug Buyers In Nexium Pay-For-Delay Suit
- Rise Of Crossover Rounds: More Biotechs Eye Late-Stage Cash
- Bayer, Merck Hit With More Suits Over Avelox Nerve Damage
- USPTO Posts Update On Alice, Mayo, Myriad Rules
- Novartis Looks To Kill Gleevec Antitrust Suit
- AbbVie Says Chancery Rightly Axed Suit Over Failed Inversion
- NuVasive Inks $14M FCA Deal Over Kickbacks, Off-Label Uses
- Bio-Rad Says Former GC Was Fired For 'Abusive' Conduct
- Corporate Tax Code Needs Reform, Senate Panel Hears
- Utah High Court Sends Amnesiac Atty's Fee Dispute To Jury
- Prosecution Of Off-Label Speech In A Post-Caronia World
- Final Thalidomide Claim Is Time-Barred, GSK Tells 3rd. Circ.
- Actavis Blasts USPTO Decision In Opana Row
- Medicare Contractors Overpaid $36M For Drugs, Audit Finds
- PTAB To Scrutinize Xyrem Patents In Inter Partes Review
- Novartis Spins Off 3 Drugs To New UK Biopharma Company
- US Seeks Criminal Contempt Over Herbal Supplement Store
- European Commission OKs Mylan's Hostile Perrigo Takeover
- Celgene Wants Sanctions For 'Abusive' AIA Review Petition
- Why UK Backed Off From Loyalty Rebate Abuse Probe
- J&J, Janssen Face Risperdal Suit From Cherokee Nation
- The Top Product Liability Cases Of 2015: Midyear Report
- Janssen Hit With Another Levaquin Nerve Damage Suit
- Caris Employees Get $16.3M After Co. Sharply Devalued Stock
- Herbalife Again Escapes Shareholder Class Action
- Glenmark Infringed Bayer's Finacea Patent, Judge Rules
- Ex-Teva Exec. Blames Firing On FCPA Probe Cooperation
- Robbins Geller Named Lead Counsel In Glaucoma Drug Row
- Purdue Loses Reconsideration Bid In Chicago's Painkiller Suit
- Ohio Doc Must Face Claims In Meningitis MDL, Court Rules
- House OKs Congressional Review For Major Regulations
- Contact Lens Cos. Call Utah Pricing Law Unconstitutional
- Locke Lord Booted From Supplement False Ad Class Action
- Hikma To Pay $2.7B For Boehringer US Unit
- 4th Circ. Won't Reconsider GNC Win In False Ad Suit
- Cancer Biotech NantKwest's $207M IPO Trumps Expectations
- Teva Tells Fed. Circ. AstraZeneca Suit Belongs In Delaware
- FDA Floats Plan For Measuring Drugmaker Quality
- NJ Pharma Co. Revives Lupus Product Row With FDA
- Sullivan Scores For New Client Teva In $40.5B Allergan Deal
- Provigil Buyers Win Class Cert. In Pay-For-Delay Fight
- GSK Pushes 3rd Circ. To Rehear Lamictal Pay-For-Delay Suit
- Drug Cos. Say Rulings Don't Boost Actos Pay-For-Delay Suit
- Manufacturers Seek Robust IP, Investment Rules In TPP
- Shire Allowed Access To Confidential Info In Adderall Row
- 3rd Circ. Won't Rethink Girardi Keese Avandia Fee
- FTC Asks AbbVie, Others For Deal Docs In Pay-For-Delay Suit
- Anthem Sued Again Over Gilead Hep C Drug Coverage
- Teva Inks $40.5B Deal For Allergan Generics Unit
- Law360's Trial Aces Make Winning Look Easy
- Medtronic Asks Justices To Weigh Patent Fight Under Commil
- Biolitec Takes $70M Contempt Ruling To High Court
- VA Small Biz Contract Lacked Sufficient Research, GAO Says
- Convicted McDonnell Asks 4th Circ. For En Banc Rehearing
- FDA Faces Backlash On Drug Compounding Limits
- Knobbe Martens Blasts DQ Bid In Patent Dispute
- Hundreds Of NJ Suits Involving New Accutane Label Tossed
- Judge Halts, Mostly Tosses Whole Foods Homeopathy Suit
- Bayer Can't Nix Claims In Mirena IUD Blindness Lawsuit
- No Ban On Utah Contact Lens Pricing, 10th Circ. Hears
- 11 Cos. Set Sights On $2.4B In End-Of-July IPO Rush
- Sports Supplement Co. Hits Rival With False Ad Suit
- Medtronic Can't Escape Patent Suit, Texas Judge Rules
- Bristol-Meyers, Pfizer Sued Over Blood Thinner Death
- Rimon Snags Ex-Gunderson Deal-Maker In San Francisco
- Senators Seek To Block Feds From Punishing Pot Banks
- The Contentious Biosimilar Nonproprietary Naming Debate
- REBUTTAL: The Problem With 3rd-Party Litigation Financing
- Eli Lilly Slams 'Startling' Teva Brief In Alimta Patent Fight
- Juror's Google Search Triggers New Tylenol Death Trial
- Lupin Shells Out $880M For NJ-Based Pharma Co.
- Mylan Foundation Moves To Thwart Teva $40B Hostile Bid
- Novo Nordisk Objects To Expert In ITC Drug Patent Row
- Biotech Says Solomon Isn't Owed $3.7M For AstraZeneca Deal
- Biotech Sues Patent Management Firm For Overcharging
- GSK Faces Wave Of Zofran Birth Defect Suits
- Baylor Sued By Research Doctor Over Patent Royalties
- Pfizer Patent Not Indefinite In Sandoz IP Row, Judge Says
- Firm Must Pay MDL Fee After Avandia State Settlement
- Endo's Opana Patent Survives AIA Challenge By Amneal
- Steris Corp. Accused Of Selling Tainted Goods To Gov't
- Gray Reed Knocks Medtronic's Patent Suit 'Smear Campaign'
- Recent Lessons In D&O Fee Advancement And Indemnification
- Judge Won't DQ Skadden In Ex-Oriole Insider Trading Case
- Mylan Investors Slam Tax Inversion As Anti-Teva Ploy
- Teva Escapes Merck's Patent Suit Over Generic Nasonex
- Watson Moves To Undo Amarin's Exclusivity Win Over FDA
- Shire Rehearing Bid Parrots Rejected Claims, Fed. Circ. Told
- Herbalife Seeks Discovery To Identify Negative Tweeter
- Teva, Boehringer Get Quick Appeal In Pay-For-Delay MDL
- Eli Lilly Dodges 2nd Cymbalta Label Class Cert. Bid
- How To Become The Highest-Paid Partner At Your Firm
- Medtronic Seeks $6M In Fees In Long-Running Patent Case
- Hughes Hubbard Adds Ex-Kenyon Atty To NY Office's IP Group
- Gibson Dunn Guides St. Jude In $3.4B Deal For Thoratec
- Informing The Artisan: Reasonable Certainty In Patent Claims
- Ex Ante Vs. Ex Post: Janis Joplin's Yearbook Revisited
- Receptos Investor Sues To Block Celgene's $7.2B Buyout
- 5 Takeaways After Fed. Circ. Amgen-Sandoz Ruling
- Cephalon Can't Ditch FCA Claims In Off-Label Marketing Suit
- Amgen, Sandoz Both Winners And Losers At Federal Circuit
- SAC Beats Investors' Privilege Claims In Insider Trading Suit
- Chancery Tosses Claims Over Abbott Labs' AbbVie Spinoff
- Pfizer Gets Partial Win In Sandoz Generic Bladder Drug Row
- Deals Rumor Mill: Thoratec, Qualcomm, Nokia Here
- FTC Asks For Review Of AbbVie Pay-For-Delay Ruling
- Zoloft MDL Plaintiffs Agree To Pull Birth Defect Reports
- Lupin To Take Fight Over Pay-For-Delay Probe To 4th Circ.
- Patheon Wins Fees For Doc Fight In Procaps Merger Suit
- Horizon Pharma Raises Offer For Depomed Takeover
- SIGA Trustee Fights $700K In Executive Bonuses
- Gray Reed Says Medtronic's DQ Bid Can't Delay Patent Case
- DLA Piper Snags Ex-Cooley M&A Pro For Bay Area Team
- Fed. Circ. Amgen-Sandoz Ruling Extends Biologics Exclusivity
- Ensure Drinkers Hope Doctors' Notes Can Cure Class' Flaws
- Chicago Fights For Clarity In Drug Marketing Suit
- Atty Says False Ad Client's Residency Doesn't Merit Sanction
- Eli Lilly Can't Shake Prozac Heart Birth Defect Suit
- Alzheimer's Biotech Targets $125M IPO
- Reed Smith Adds India And Outsourcing Expert In NY
- Biolitec Tells 1st Circ. To Nix $70M Contempt Order
- Maquet Accused Of Retaliation By Ex-Compliance Exec
- Retailers' Claims Trimmed In Lidoderm Pay-For-Delay Case
- Stradley Ronon Nabs Ex-McCarter & English Litigation Pro
- Mayer Brown Nabs FDA Expert From Jones Day In DC
- Gowlings Adds IP Atty, Patent Agent As Vancouver Partner
- Procuring Personalized Medicine Patents In US Vs. Europe
- Takeda Ruling On Expert Standards To Ripple Beyond Actos
- Becton Sued For Squeezing Out Rivals With Safer Syringes
- CVS Gets OK For $7.4M Deal In Pharmacist OT Class Actions
- 6 IPOs Eye $1.04B In Coming Week
- Fed. Circ. Affirms Nixing Of Columbia's DNA Patent Claims
- Kirkland Warns Of Conflicts 'Sea Change' In Mylan Row
- Mylan Can Face Hatch-Waxman Suit In Del., Fed. Circ. Hears
- Big Pharma's TPP Protections For Biologics Face New Attacks
- Girardi Keese Asks Full 3rd Circ. To Review Avandia Fee Fight
- Inside FDA Regulation Of Antibody Drug Conjugates
- Pharma Lobby Wants Some Patents Exempt From AIA Review
- Ex-Reckitt Exec's Firing Case Can Proceed In NJ, Judge Says
- Alere Draws Up $220M In Deals To Beef Up Diagnostics Biz
- Endo Whistleblower Gets 24% Cut Of $140M FCA Deal
- $6M Takeda Verdict Reinstated In 1st Actos Cancer Trial
- Lowenstein Boosts White Collar Practice With Merck Counsel
- A New Look At An Old Medical Device Warranty Safe Harbor
- CR Bard Gets 1 of 2 Claims Tossed In Stent Patent Battle
- Lab Asks For Relief From Drugmaker's $3M Damages Claim
- Fed. Circ. Won't Vacate $2.25M Verdict In Argentum IP Row
- Inside The Recent Surge In Cancer Biotech IPOs
- Pfizer Says Zoloft Plaintiffs Stirring 'False Emergency'
- 3 Takeaways From FDA's Branded Drug User Fee Workshop
- House Approves Medicare Assisted Speech, Home Care Bills
- OpenGate Sanctioned In Thermo Fisher Fraud Suit
- NJ Expands Employer Liability In Ethicon Whistleblower Case
- OPINION: Litigation Finance Can Help Break The Glass Ceiling
- Bayer's Flanax Claim 'Distorts' Lanham Act, 4th Circ. Told
- McKesson Can Appeal Darvocet Remand Decision: Judge
- WilmerHale Nabs Ex-McDermott Patent Pro In LA
- Zoloft Plaintiffs Seek Pfizer's Contacts With Study Authors
- Bayer MDL Firms Certified As A Class Of Their Own
- Gay Blood Donation Policy Is Discriminatory, Lawmakers Say
- Liberty Medical Estate Gets Nod For Ch. 11 Plan
- WL Gore Asks High Court To Take On $1B Patent Case
- Lawmakers Train Sights On Part D Insurers Over Billing Fraud
- PTAB Mostly Rejects Lupin's AIA Review Of HIV Drug Patent
- LabCorp Keeps OT Suit In Calif. Federal Court
- Proskauer Advises Celgene In $7.2B Receptos Acquisition
- Consumer Groups Urge FTC To Block Teva's Hostile Mylan Bid
- The Biggest Calif. Court Decisions So Far In 2015
- Cooley Boosts NY Capital Markets Team With Ex-Skadden Atty
- Pfizer Moves To Quell EU Concerns On $17B Hospira Deal
- A 1st Look At PTAB's Plan For Overlapping Proceedings
- Abbott Board Seeks To Nix Suit From Spinoff's Shareholders
- Medtronic's DQ Attempt Is A 'Tactical Ploy,' Gray Reed Says
- Sanofi-Aventis Shakes FCA Suit Over Lovenox
- 5 Takeaways From FDA's Medical Device User Fee Workshop
- Avalanche Hit With 2nd Stock Drop Suit Over Eye Drug Study
- Drug Co. Celladon Faces Stock Drop Suit After CEO's Exit
- Merck Withholding Pay Data In Sex Bias Suit, Judge Told
- Lincare Dodges Bulk Of FCA Suit Over Medicare Marketing
- ANI Pharma Nabs $25M Teva Generic Drug Portfolio
- The FDA's Track And Trace Enforcement Delay: Stay Alert
- Senate Bill Would Ease Bank Access For Legal Pot Shops
- Plaintiffs Can Submit New Evidence In Scotts Bird Food Case
- DOJ's Maligned Integrity Unit Returns To Form With Big Win
- FTC Chair Says $1B Cephalon Deal Puts Cos. On Notice
- Idenix Investors Blame $12M Loss On Unclaimed-Stock Seizure
- 8 IPOs Set Sights On $600M In Coming Week
- Merck Says Bid To Amend Vioxx Investor Suit Is Too Late
- AbbVie, Teva Can't Make Niaspan Buyers Give Up Sales Data
- Endo's AMS Unit Settles More Than 100 Vaginal Mesh Suits
- FTC Gets Shot At Reviving AbbVie Pay-For-Delay Claims
- Avalanche Hit With Stock Drop Suit Over Eye Drug Study
- Haynes And Boone Nabs 2 IP Attys For Hatch-Waxman Group
- House Passes Sweeping 21st Century Cures Act
- FDA Toughens Stance On OTC, Prescription Pain Relievers
- Ex-Va. Gov. Loses Appeal Of Corruption Conviction
- A Possible Solution To Europe's Pharma Financing Problem
- Biogen Wants Kyle Bass To Give Up Financial Docs At PTAB
- San Jose Sues Monsanto, Pfizer Over PCBs
- 9th Circ.'s FCA Ruling To Spark More Whistleblower Fights
- Depomed Patents Challenged By Purdue Survive AIA Review
- Obama Troubled With 21st Century Cures Act Funding
- SEC Settles With 2 In Pot Stock Pump-And-Dump Case
- 4th Circ. Raises Bar For False Ad Plaintiffs In GNC Ruling
- 4 FCA Suits Allege Biogen Paid Kickbacks To Prescribers
- Norton Rose Nabs Ex-Sandoz North America GC
- AstraZeneca Divests Gastrointestinal Drug For $215M
- Fenwick Nabs Ex-Dechert Life Sciences Pro For IP Practice
- Norton Rose Fulbright Lures IP Atty From Allen & Overy
- Marijuana Dispensary Can't Deduct Biz Costs From Taxes
- CORRECTED: Jury Finds Boston Scientific Infringed Stent Patent
- NJ Is No Exception To The Learned Intermediary Doctrine
- How To Improve Drafting Language In Chemical Arts Patents
- Calif. High Court Won't Rehear Cipro Pay-For-Delay Ruling More
- Nexsen Pruet Adds Ex-Ward & Smith IP Atty
- SC Court Shaves $12M Off Risperdal Fine Against J&J Unit
- Eli Lilly Fights Plaintiffs' Expert Testimony In Cymbalta Suit
- Nature's Way Ginkgo Pills Don't Boost Memory, Suit Claims
- AstraZeneca Escapes Nexium False Ad Suit
- Texas Judge Tells Remoxy Plaintiffs To Refile Class Action
- FTC Ends Memory Pill False Ad Suit For $1.4M
- Cubist Pushes Fed. Circ. To Revive MRSA Drug Patents
- Kirkland Trying To Dupe Court In DQ Row, Mylan Says
- Canada's Gowlings To Merge With UK's Wragge Lawrence
- Biotech Says Solomon Wasn't Involved In AstraZeneca Deal
- 3rd Circuit To Link Up Effexor, Lipitor Pay-For-Delay Appeals
- New Bill Expanding Telehealth Coverage Gets Industry Support
- Teva, Mylan And The Impact Of 'Foreign' On HSR Analysis
- Pharma Co. CorMedix Faces Investor Suit After Stock Drop
- Insurer Knew Of Suit Years Before It Claims It Did, Court Told
- Omnicare, DOJ Strike Deal In Abbott Labs Kickback Suits
- Wash. Court Affirms Intuitive Win In Surgery Death Suit
- Medical Device Co. Pushes FCC For Ultra-Wideband Waiver
- Judge Grills Amarin, FDA Over Off-Label Promo Statements
- FDA Must Handle Politics Over Female Libido Drug, Docs Say
- En Banc 9th Circ. Loosens FCA's Original Source Requirement
- Judge Ices Zoloft MDL Hearing Over Potential Study Error
- BMS Sues Merck As Soon As USPTO Grants Cancer Patent
- Health Care Litigator Joins Seyfarth Shaw In Houston
- Horizon Pharma Makes $3B Hostile Bid For Depomed
- Endo, Impax Look To Nix Opana Pay-For-Delay Suits
- AstraZeneca, Cephalon Pay $54M To End Medicaid Rebate Row
- Fee Row In Bayer GMO Class Action Can Proceed, Judge Says
- Drug Cos. Fight Chicago's Clarification Bid After Dismissals
- Allergan To Pay $125M For Dry Eye Medical Device Co.
- AbbVie Says Reconsideration Not Needed In FTC Row
- Sheppard Mullin Adds Ex-Loeb & Loeb Corporate Atty
- Life Sciences Cases To Watch In The 2nd Half Of 2015
- Deals Rumor Mill: Teva, Mylan, Philip Morris, China Network
- FTC, Fla. AG Ask Judge To Stop Lifewatch Robocalls
- 5 Firms Top $300B In Deals During 1st Half Of 2015 M&A Boom
- How To Pitch A Pharmaceutical Company
- Knobbe Martens Twisting Facts In DQ Row, Court Told
- Shire Says Fed. Circ. Misapplied Teva Deference Standard
- Gould & Ratner Nabs Loeb & Loeb Atty To Head Its IP Group
- FDA Warns Online Drug Buyers Of Fake Generic Valium
- White House Orders Updated GMO Rules Amid Criticism
- Georgia AG Wades Into Mesh Implant Appeal In 4th Circ.
- Health Cases To Watch In The 2nd Half Of 2015
- VC-Backed Natera Beats Expectations With $180M IPO
- J&J Beats Bid For New Trial In Philly Risperdal Case
- Girardi Keese Can't Avoid Recovery Sharing In Avandia Suits
- Daiichi Sankyo Loses Patent Term Adjustment Challenge
- Brand Battles: Bayer, Philips, HBO, Red Bull
- Fla. Jury Clears IP Firm Of Malpractice In Legal Fees Flap
- The Biggest Pa. Court Decisions Of 2015: Midyear Report
- FTC Asks Court To Review AbbVie Pay-For-Delay Dismissal
- Regulators Are Cracking Down On Drug Disposal
- Amarin Ducks Securities Action Over Vascepa Denial
- Fed. Circ. Wipes Out Medicines Co.'s Angiomax Patents
- Judge Nixes Lupin Pay-For-Delay Suit Against Alaska AG
- M&A Boom Soars To Highest First-Half Clip In 8 Years
- Swiss Pregnancy Tests Deliberately Misleading, Judge Rules
- Teva Tells DC Circ. Ranbaxy Deserved Drug Revocation
- FDA Reviewing Codeine Cough Medicine Safety For Children
- 1 Firm Tops June IPO Activity As Volume Hits New Heights
- Magistrate Urges Dismissal Of Merck's Generic Nasonex Suit
- Kirkland Guides Madison Dearborn On $715M Rehab Biz Buy
- Pfizer Says Plaintiffs Are Rehashing Nixed Zoloft Testimony
- Xellia Found To Infringe Merck Anti-Fungal Med Patent
- Skadden Not Conflicted In Insider Trading Case, Court Told
- Former Pfizer Compliance Attorney Joins Morgan Lewis
- Eli Lilly Hit With IP Suit Over Cialis Use
- Life Tech Takes Gene Testing Patent Loss To High Court
- FDA Targets Unapproved Ear Drops After Infant Death
- An 'Exceptional Case' One Year After Octane: Part 2